Poster: Primary Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro

• DA
• November 24, 2023

The RepliGut SOT 2023 poster, presented at the 2023 SOT meeting, features collaborators from Janssen Pharmaceuticals describing their use of the RepliGut® Planar Platform to distinguish between compounds with different potencies for the JNJ epigenetic target X with a known in vivo GI liability. The poster describes testing a limited set of reference compounds including drugs with a high (> 50%) and a low (0-4%) incidence of diarrhea in the clinic.

https://www.altisbiosystems.com/wp-content/uploads/2023/09/JNJ_poster1_SOT2023.pdf